Inflammatory Breast Cancer Clinical Trials
The Morgan Welch Inflammatory Breast Cancer (IBC) Research Program is committed to finding what causes inflammatory breast cancer and identifying new treatment options. We are conducting a number of treatment-based studies and a wide variety of lab-based studies to understand this disease better. The list below highlights the ongoing trials being run by the IBC Research Program and clinic. Additional IBC clinical trials can be found at ClinicalTrials.gov.
If you would like more information about becoming involved with our clinical trials in general, you may email our program at ibcp@mdanderson.org.
IBC Registry
Protocol 2006-1072: Inflammatory breast cancer registry (Also open at select IBC Connect sites, through MD Anderson Cancer Network)
Contact Info:
Study Manager: Angela Alexander, Ph.D., 713-792-9137 or aalexand@mdanderson.org
Principal Investigator: Vicente Valero, M.D., 713-563-0751 or vvalero@mdanderson.org
The IBC Registry is our master banking study, that allows us to collect blood and tissue samples to support the entire research program at MD Anderson and beyond. All patients with diagnosed or suspected IBC are eligible to be enrolled, regardless of treatment choices.
Currently Open Trials for Newly Diagnosed IBC
Protocol 2023-0100: TRUDI: A phase II study of neoadjuvant Trastuzumab deruxtecan and Durvalumab for stage III, HER2-expressing Inflammatory Breast Cancer
Contact Info:
Study Manager: Angela Marx, R.N., 713-792-5355 or anmarx@mdanderson.org
Principal Investigator: Rachel Layman, M.D., 713-745-8401 or rlayman@mdanderson.org
Currently Open Trials for Adjuvant Treatment
No adjuvant trials are currently enrolling.
Currently Open Local Therapy Trials
Protocol SWOG 1706: A phase II randomized study of Olaparib (NSC-747856) administered concurrently with radiotherapy versus radiotherapy alone for inflammatory breast cancer
Contact Info:
Wendy Woodward, M.D., Ph.D. 713-563-8481 or wwoodward@mdanderson.org
Currently Open Trials for Metastatic/Recurrent IBC
IBC-specific trials
None currently
Trials that allow IBC patients with logical targets
Protocol 2020-0198: Neratinib and Capmatinib combination (phase 1b/II) in metastatic breast cancer and inflammatory breast cancer patients with abnormal HER2 and c-MET pathway activity as measured by CELsignia signaling analysis test
Contact Info:
Study Manager: Vivian Chiv, M.S.N., R.N, 713-792-4157 or vychiv@mdanderson.org
Principal Investigator: Rachel Layman, M.D., 832-829-4125 or rlayman@mdanderson.org
Protocol 2022-0315: Phase Ib study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer
Contact Info:
Study Manager: Angela Marx, R.N., 713-792-5355 or anmarx@mdanderson.org
Principal Investigator: Senthil Damodaran, M.D., Ph.D., 832-829-4307 or sdamodaran@mdanderson.org